Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 13 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 3 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 6 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 9 months ago New First-Line Option for Pancreatic Cancer Approved - 11 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 11 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago FDA OKs First Drug for Nasopharyngeal Carcinoma - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - about 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - about 1 year ago Pembrolizumab Wins FDA Approval in Operable Lung Cancer - about 1 year ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 13 days ago Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - about 1 month ago FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - 4 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 6 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - 10 months ago FDA Approves Irinotecan Liposome for Metastatic Pancreatic Adenocarcinoma - 10 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - about 1 year ago FDA Grants Priority Review for Pembrolizumab in Progressive Cervical Cancer - over 1 year ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - about 2 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - 10 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 12 months ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - 12 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - about 1 year ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC - 3 months ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 4 months ago FDA Grants Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma - 4 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 9 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 9 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 10 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 11 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 7 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 9 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - about 1 year ago
7	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer - 9 months ago FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 10 months ago
8	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest - 10 months ago
9	Pharmacy Times Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment - 10 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 11 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - about 1 year ago Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer - about 1 year ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - about 1 year ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - about 1 year ago

Journalists covering paclitaxel